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Abstract
Synapse-asssociated protein-97 (SAP97) is responsible for the trafficking of both glutamate receptor subunits, GluR1 and NR2A, and
-secretase ADAM10 to the synaptic membrane. Here we evaluate the trafficking capability of SAP97 in Alzheimer disease (AD) patients’
rain. We analyzed autoptic hippocampus and superior frontal gyrus, respectively as an affected and a less affected area, from 6 AD patients
Braak 4) and 6 healthy controls. In hippocampus, but not in superior frontal gyrus, of AD patients, ADAM10 and GluR1 synaptic
embrane levels are altered while NR2A localization is not affected. Both immunoprecipitation and pull-down assays demonstrated that
AP97 failed to correctly couple to ADAM10 and GluR1, but not to NR2A. These findings not only indicate SAP97 as a point of
onvergence between amyloid cascade and synaptic failure in AD, but also allow a different interpretation of AD which can be now
erceived as synaptic trafficking defect pathology.
2012 Elsevier Inc. All rights reserved.
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s1. Introduction
Alzheimer disease (AD) is the most common form of
dementia. Neuropathology of the full blown stage of the
disease reveals the presence of both amyloid aggregates and
neurofibrillary tangles, indicated as hallmarks of the dis-
ease. In addition, quantification by both immunostaining
and electron microscopy of synaptic markers documented
significant decrease in synaptic density in both cortex and
hippocampus of AD patients’ brains and biochemical anal-
yses confirmed a similar loss in both pre- and postsynaptic
components (Bertoni-Freddari et al., 1996, 2003; DeKosky
and Scheff, 1990; Masliah et al., 2001; Reddy et al., 2005;
Scheff et al., 2007; Terry et al., 1991). This initial decrease
* Corresponding author at: Department of Pharmacological Sciences,
University of Milano, Via Balzaretti 9, 20133 Milano, Italy. Tel.: 0039 02
50318374; fax: 0039 02 50318284.
E-mail address: monica.diluca@unimi.it (M. Di Luca).
1 These 2 authors contributed equally to this work.
0197-4580/$ – see front matter © 2012 Elsevier Inc. All rights reserved.
doi:10.1016/j.neurobiolaging.2010.09.015of synaptic contacts seems not to correlate with loss of
neuronal cell bodies thus suggesting synaptic failure and
subsequent synaptic loss as a very early event in AD patho-
genesis (Bertoni-Freddari et al., 2003; DeKosky and Scheff,
1990).
More recently it has been proposed that the complex
cascade of molecular events eventually leading to synaptic
failure is the consequence of progressive accumulation and
aggregation of amyloid  (A) peptide (Hardy and Selkoe,
2002). However, cellular and molecular targets of A
and/or early molecular events initiating the process of syn-
aptic impairment are still unknown.
A peptide is located within the type I transmembrane
myloid precursor protein (APP) at the junction between the
ntralumenal and transmembrane domains. Two enzymatic
teps liberate A from APP. In the first, “‘-cleavage’”
tep, -site APP-cleaving enzyme (BACE) (Vassar, 2001)
cleaves APP at or near the N-terminus of the A peptide;
then, in the second, or “‘-cleavage’” step, the membrane-
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422.e2 E. Marcello et al. / Neurobiology of Aging 33 (2012) 422.e1–422.e10bound C-terminal APP fragment (CTF99) generated by BACE
goes on to be cleaved by the -secretase. Alternatively, APP
an be subject to the -secretase cleavage mediated by A
disintegrin and metalloproteinase 10 (ADAM10) (Lammich et
al., 1999; Postina et al., 2004), which occurs within the se-
quence of A, thus precluding the formation of the amyloido-
genic fragments.
ADAM10 is synthesized in an inactive form, which is
proteolytically cleaved during its forward transport along
the secretory pathway, enabling enzyme activity at the
plasma membrane (Anders et al., 2001; Lammich et al.,
1999).
We have previously reported that ADAM10 binds syn-
apse-associated protein-97 (SAP97) and this direct interac-
tion governs ADAM10 recruitment to synaptic membrane
and its activity. This mechanism represents a novel pathway
of activation of -secretase physiological APP cleavage in
neurons at synaptic sites (Marcello et al., 2007).
SAP97 belongs to the membrane-associated guanylate
kinase (PSD-MAGUK) family of synaptic scaffolding pro-
teins which are key players in the structural organization of
the excitatory glutamatergic synapse (Kim and Sheng,
2004). Some members of this family, i.e., PSD95/93 are in
fact involved in spines’ maturation, clustering of ionotropic
glutamate receptors subunits at synaptic sites, while
SAP102 and SAP97 have been shown to be essential part-
ners for local synaptic trafficking of ionotropic glutamate
receptors’ subunits, i.e., amino-3-hydroxy-5-methylisox-
azole-4-propionic acid (AMPA) and N-methyl-D-aspartic
acid (NMDA) subunits (Elias and Nicoll, 2007). In partic-
ular, SAP97 is implicated in the precise targeting and clus-
tering of AMPA receptor subunits GluR1 (Nakagawa et al.,
2004; Sans et al., 2001; Schluter et al., 2006) and NMDA
receptor subunit NR2A (Gardoni et al., 2003; Mauceri et al.,
2007) through PDZ1 and 2 domains. Because of SAP97
involvement in trafficking of relevant molecules to the syn-
apse, its role in neurodegenerative diseases has been largely
Table 1
Demographic and neuropathological characteristics of AD and HC cases
Subjects Gender Age at death, years PMD
1 (AD) F 91 3.45
2 (AD) F 91 4.15
3 (AD) F 86 4.10
4 (AD) F 86 5.05
5 (AD) M 81 4.05
6 (AD) F 86 5.55
Mean  SD 86.83  4.18 4.39
1 (HC) F 84 4.45
2 (HC) F 81 6.40
3 (HC) M 80 7.15
4 (HC) M 84 7.05
5 (HC) F 85 5.00
6 (HC) F 85 4.40
Mean  SD 83.17  2.17 5.74
AD, Alzheimer’s disease; CSF, cerebrospinal fluid; F, female; HC, healthy contraddressed (Nash et al., 2005; Sato et al., 2008; Wakabayashi
et al., 1999).
Moreover, an emerging concept in neuroscience is that
activity dependent regulation of local trafficking of different
synaptic proteins represents the basis of plasticity and, when
dysfunctional, of synaptic failure occurring in many neuro-
degenerative diseases.
Here we explored the possibility that a defect of SAP97
capability to traffic synaptic proteins, both glutamate recep-
tors subunits and -secretase ADAM10, could represent
ne of the initial molecular events leading to synaptic fail-
re in AD, eventually merging amyloid cascade and synap-
ic failure.
. Methods
.1. Characteristics of the subjects
The hippocampus (Hp) and the superior frontal gyrus
SFG) from late onset/sporadic AD patients (AD; n  6)
and healthy controls (HC; n  6) were obtained from the
Netherlands Brain Bank. Stringent criteria were used in the
case selection of human brain tissues employed in this
study. HC have no history of psychiatric or neurological
disease and no evidence of significant age-related neurode-
generation. Braak and Braak criteria were used to categorize
AD tissues in accordance with established guidelines (Braak
and Braak, 1991). As previously reported, these criteria are
based on the distribution of neurofibrillary tangles (NFTs),
which are seen first in the transentorhinal area (stage 1),
spread to the entorhinal region (stage 2), extend to the
hippocampus proper (stage 3), increase in number there
(stage 4), and involve the association neocortex (stage 5),
and finally the primary cortex (stage 6). These stages are
divided into the entorhinal (stage 1–2), limbic (stage 3–4),
and neocortical (stage 5–6) phase corresponding, respec-
tively, to cognitively normal, cognitively impaired, and de-
mented patients. Demographic and clinical characteristics
pH CSF Brain weight, g Braak level
6.36 1011 4
6.27 1202 4
6.34 1083 4
6.62 998 4
6.42 1253 4
6.85 950 4
6.48  0.13 1082.83  114
6.26 1179 1
7.16 1164 1
5.8 1376 0
5.9 1385 1
6.72 1257 1
6.71 1165 2
6.43  0.57 1254. 33  105.03, hours
 0.57
 1.22ols; M, male; PMD, postmortem delay.
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422.e3E. Marcello et al. / Neurobiology of Aging 33 (2012) 422.e1–422.e10of AD patients and HC are shown in Table 1. AD patients
fulfilled Braak 4 stage. Accordingly, in AD cases there were
tangles and neuritic plaques in Hp, whereas the amount of
plaques in SFG closely resembled HC. All procedures were
in accordance with the National Institutes of Health (NIH)
Guide for the Care and Use of Laboratory human tissue and
were approved by the Ethics Committee of the University of
Milan, Italy.
2.2. Triton insoluble synaptic membrane (TIF) and
soluble fraction (S2) preparation
Triton insoluble fraction (TIF), a fraction highly enriched
in all categories of postsynaptic density proteins (i.e., re-
ceptor, signaling, scaffolding, and cytoskeletal elements)
absent of presynaptic markers, and soluble fraction S2, were
obtained as previously described (Gardoni et al., 2001;
Marcello et al., 2007). In order to avoid protein degradation,
AD samples were paired to HC samples and processed at
the same time. The relative values for each case were
replicated in duplicate experiments, considering for each
paired sample the ratio AD/HC.
2.3. Immunoprecipitation (i.p.)
Aliquots of 50 g (for ADAM10/SAP97 and GluR1/
AP97 immunoprecipitation [i.p.]) or of 70 g (for SAP97/
R2A i.p.) of homogenate obtained from the S2 purification
rom Hp and SFG of HC and AD were incubated overnight
t 4 °C in a buffer containing 200 mM NaCl, 10 mM
thylene-diaminetetra-acetic acid (EDTA), 10 mM
a2HPO4, 0.5% NP-40, 0.1% sodium dodecyl sulfate
(SDS) in a final volume of 150 L with an antibody (Ab)
gainst ADAM10, GluR1, or SAP97. Immunoprecipitation
as been carried out as previously described (Marcello et
l., 2007). Beads were collected by centrifugation and the
upernatants were loaded onto sodium dodecyl sulfate -
olyacrylamide gel electrophoresis (SDS-PAGE) at 6% and
evealed by either anti-SAP97 or anti-NR2A.
.4. Western blotting (WB)
30 g of proteins from homogenate and TIF were sep-
rated on 6% and 7% SDS-PAGE, transferred to a nitrocel-
ulose membrane and probed with the corresponding pri-
ary Ab, followed by incubation with horseradish
eroxidase-conjugated secondary Ab. To analyze APP C-
erminal fragments (CTFs), TIF proteins were separated on
15% Tris-Tricine SDS-PAGE and Western blot (WB)
nalysis was performed with 4G8 Ab. Membranes were
eveloped using electrochemiluminescence reagent (Amer-
ham Biosciences, Buckinghamshire, UK).
.5. Cloning, expression, and purification of glutathione
-transferase (GST) fusion protein
Glutathione S-transferase (GST)-ADAM10 C-terminal
omain (Ct) fusion protein contains the cytoplasmic domain
f ADAM10 (695–749) (Marcello et al., 2007) and GST-R2A the sequence of NR2A C-terminal domain from
mino acid 1349–1464 (Gardoni et al., 1999). GST-GluR1
-terminal domain (Ct) was kindly provided by M. Passa-
aro (DTI Dulbecco Telethon Institute, Milano, Italy) and
ncludes the sequence of GluR1 cytoplasmic tail. GST fu-
ion proteins were expressed in Escherichia coli and puri-
ed on glutathione agarose beads (Sigma Aldrich, St. Louis,
O, USA) as previously described (Gardoni et al., 2001).
.6. Pull-down assay
Aliquots of homogenate from either Hp or SFG of AD
atients and HC subjects were diluted with Tris Buffered
aline (10 mM Tris and 150 mM NaCl) to a final volume of
mL and incubated 2 hours with 40 L of GST saturated
ith the C-terminal domain of ADAM10 or the C-terminal
omain of NR2A or the C-terminal domain of GluR1 or
ST alone. After incubation, beads were washed 5 times
ith Tris-buffered saline and 0.1% Triton X-100. Bound
roteins were resolved by SDS-PAGE and subjected to
mmunoblot analysis with monoclonal SAP97 Ab and
onoclonal GST Ab.
.7. Antibodies
The following Ab were used: monoclonal antibody (mAb)
2C11 (raised against N-terminal domain of APP), mAb 4G8
against 17–24 amino acids of A), mAb anti--calcium/cal-
modulin-dependent kinase II (-CaMKII), polyclonal anti-
ody (pAb) anti-GluR1 and mAb 6E10, raised against 1–17
mino acids of A, were purchased from Millipore (Bil-
erica, MA, USA); pAb anti-ADAM10 from Abcam (Cam-
ridge, MA, USA); mAb antipan-Shank and anti GST from
euromab (Davis, CA, USA); mAb anti-SAP97 from
tressgen (Victoria, B.C., Canada); mAb anti-PSD-95 from
ffinity BioReagents, Inc. (Golden, CO, USA); pAb anti-
ctin from Sigma-Aldrich (St. Louis, MO, USA); mAb
gainst NR2A from Zymed (San Francisco, CA, USA);
nti-synaptophysin and anti-SNAP25 from Synaptic Sys-
ems (Göttingen, Germany). Peroxidase-conjugated second-
ry anti-mouse Ab was purchased from Pierce (Rockford,
L, USA) while peroxidase-conjugated secondary anti-rab-
it Ab was purchased from Bio-Rad (Hercules, CA, USA).
.8. Statistical analysis
The levels of -CaMKII, PSD-95, Shank, SAP97,
ADAM10, NR2A, and GluR1 were expressed as relative
optical density (OD) measurements, i.e., ratio between the
immunoreactivity of the protein of interest and the immu-
noreactivity of actin in each lane scanned. Data obtained by
pull-down assays were normalized on GST OD, corre-
sponding to the amount of GST fusion protein. The values
for AD patients were then expressed as percentage of HC in
the same blot  standard error of the mean (SEM). For the
analysis of CTFs, the ratio between the OD of CTF83 and
CTF99 was measured. Statistical evaluations were performed
by Student t test or Pearson correlations, as appropriate.
W422.e4 E. Marcello et al. / Neurobiology of Aging 33 (2012) 422.e1–422.e10Fig. 1. Synaptic levels of A disintegrin and metalloproteinase 10 (ADAM10) and GluR1 are altered in hippocampus (Hp) of Alzheimer’s disease (AD)
patients. (A) Western blot (WB) of homogenate and triton insoluble fraction (TIF) obtained from Hp of AD patients and healthy controls (HC) performed
with anti--CaMKII, anti-PSD-95 and anti-Shank antibodies. No alterations were found in the levels of these proteins in total homogenate and in TIF. (B)
B of homogenate and TIF obtained from superior frontal gyrus (SFG) of AD patients and HC performed with anti--CaMKII, anti-PSD-95 and anti-Shank
antibodies. No alterations were found in the levels of these proteins in total homogenate and in TIF. (C) WB of homogenate obtained from SFG of AD patients
and HC performed with anti-synaptophysin and anti-SNAP25 antibodies. No alterations were found in the levels of these proteins in total homogenate (D)
WB of homogenate and TIF obtained from Hp of AD patients and HC performed with anti-SAP97, anti-ADAM10, anti-GluR1, and anti-NR2A antibodies.
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3.1. At Braak 4 stage of disease, synaptic structure is not
affected while APP metabolism is shifted toward
amyloidogenesis in Hp but not in SFG
Although current available animal models have been
extremely informative about key pathogenic pathways of
AD, to assess the relevance of SAP97 complexes with its
synaptic partners in AD pathogenesis we exploited autoptic
brain tissues obtained from 6 late onset AD patients, fulfill-
ing criteria for Braak 4 stage, and 6 aged-matched control
subjects (HC) (Table 1).
Our experimental design implied the study of the synap-
tic role of SAP97 in the earliest phase of AD pathogenesis,
when APP metabolism is shifted toward amyloidogenesis
but the loss of synaptic structure is not prominent. Thus we
focused only on Hp, the first brain area affected by the
disease, and SFG, a less affected area used as negative
control because no significant plaque deposition was detect-
able at this stage, as revealed by neuropathology reports.
To validate our experimental design and to support neuro-
pathological data with biochemical ones, we characterized
APP metabolism, postsynaptic structural composition, and pre-
synaptic proteins in both areas of HC and AD patients’ groups.
Firstly, in Hp and in SFG, we measured release of APP
ectodomain generated by -secretase (sAPP) in the solu-
le fraction. Immunoblot experiments, performed with
E10 antibody, showed a reduction in sAPP levels in Hp
of AD compared with HC (38.8  12.7%, p  0.028,
supplementary. Fig. S1A), but not in SFG (33.7 56.4%,
p  0.05, supplementary Fig. S1A). To strengthen these
results, APP C-terminal fragments (CTFs)-CTF99 for
-cleavage and CTF83 for -cleavage-were evaluated in the
riton insoluble fraction (TIF), a fraction enriched in post-
ynaptic density proteins (Adlard et al., 2005; Kamenetz et
l., 2003; Zimmermann et al., 2004). TIF proteins were
eparated on a 15% Tris-Tricine SDS-PAGE and immuno-
lot analysis was performed with 4G8 antibody. CTF83/
TF99 ratio was significantly decreased in Hp of AD com-
ared with HC (25.85  8.5%, p  0.029, supplementary
ig. S1B), but not in SFG (23.7  25.2%, p  0.05,
upplementary Fig. S1B).
These data confirm that, at this stage of pathogenesis,
PP metabolism is shifted toward amyloidogenesis only in
p and not in SFG of AD patients.
Secondly, we evaluated possible alterations in the post-
ynaptic structure occurring at this stage of the disease. To
No alterations were found in the levels of these proteins in total homogen
in TIF were observed in AD compared with HC (ADAM10: *p  0.002, G
atients and HC performed with anti-SAP97, anti-ADAM10, anti-GluR1,
ound in the levels of these proteins in total homogenate and in TIF. NR2A
p  0.015). All data were normalized using actin. For all experiments quexperiment.his, we assessed biochemically the levels and synaptic
ocalization of the three major postsynaptic density (PSD)
omponents, i.e., Shank, PSD-95, and -CaMKII (Sheng
and Hoogenraad, 2007). Immunoblot experiments were per-
formed on total homogenate and on TIF, a fraction enriched
in postsynaptic density proteins. Quantitative analyses
showed no significant modifications of Shank, PSD-95 and
-CaMKII in total homogenate and TIF fraction of both Hp
and SFG of AD and HC, suggesting that postsynaptic struc-
ture is preserved in our experimental groups [Hp (Homo),
-CaMKII  1.8  11.9%, PSD-95  5.2  19.8%,
Shank6.9 9.6%; SFG (Homo), -CaMKII9.12
.8%, PSD-95  7.8  9.1%, Shank  22.8  12.8%;
verall: p  0.05; Hp (TIF), -CaMKII  2.9  4.5%,
SD-9520.8 15.5%, Shank80.8 41.4%; SFG
TIF), -CaMKII  5.8  7.8%, PSD-95  3.9 
14.1%, Shank  41.1  25.7%, overall: p  0.05; Fig.
1A and B].
Moreover, we evaluated the levels of the presynaptic
proteins synaptophysin and SNAP25. Quantitative analyses
revealed no significant alterations of synaptophysin and
SNAP25 in total homogenate of both Hp and SFG of AD
and HC, suggesting that the presynapse is still not affected
in our experimental conditions (Hp, synaptophysin 
4.8  9.8%, SNAP25  7.9  4.1%; SFG, synapto-
physin  13.1  28%; SNAP25  9.5  11.1%,
verall: p  0.05; Fig. 1C).
.2. Synaptic levels of ADAM10 and GluR1, but not of
R2A, are changed in Hp of AD patients
We then evaluated possible alterations of synaptic local-
zation of SAP97 and its key partners, i.e., ADAM10,
luR1, and NR2A. The levels of these proteins have been
ssessed in both total homogenate and TIF fraction.
SAP97 levels in both total homogenate and TIF of Hp
Homo, 31.4  35.1%; TIF, 24.8  25.6%, p  0.05;
ig. 1D) and SFG (Homo, 9.3  18.5%; TIF, 8.5 
.6%, p  0.05; Fig. 1E) were not affected.
Western blot analyses of TIF showed a significant reduc-
ion of ADAM10 levels in Hp of AD when compared with
C (32.6  5.6%, p  0.002, Fig. 1D) but not in SFG
18 37.1%, p 0.05; Fig. 1E). ADAM10 levels in total
omogenate were unaltered in both areas (Hp, 7.7 
1.7%; SFG, 19.5  13.2%, p  0.05; Fig. 1D and E).
GluR1 levels were significantly increased in TIF mem-
ranes of Hp of AD patients when compared with HC
ubjects (43.0  16.6%, p  0.048, Fig. 1D) but not in
significant reduction of ADAM10 levels and an increase of GluR1 levels
# p  0.048). (E) WB of homogenate and TIF obtained from SFG of AD
i-NR2A antibodies. No alterations of SAP97, ADAM10, and GluR1 were
gnificantly reduced in both homogenate and TIF (Homo: *p  0.004, TIF:
ve analysis of immunostaining is shown as percentage of HC in the sameate. A
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analyses of homogenates revealed no alterations in GluR1
total levels both in Hp (7.5  27.7%, p  0.05, Fig. 1D)
and in SFG (18.5  13.3%, p  0.05, Fig. 1E).
Immunoblot experiments detected no significant alterations
of NR2A levels both in total homogenate (6.6% 19.7%, p
 0.05, Fig. 1D) and in TIF fraction of AD Hp (34.1 
15.1%, p  0.05, Fig. 1E) compared with HC. In SFG of AD
patients compared with HC, NR2A levels were concomitantly
reduced in both homogenate and TIF (Homo,39.9 8%, p
0.004, TIF, 32.3  8.8%, p  0.015; Fig. 1E)
These data showed an altered synaptic localization of
ADAM10 and GluR1, but not of NR2A, in Hp of AD patients.
3.3. SAP97 capability to associate to both ADAM10 and
GluR1, is altered in AD patients’ Hp
Because binding to SAP97 is pivotal for these synaptic
proteins’ trafficking, the ability of SAP97 to effectively
bind its partners in AD cases and control subjects was then
evaluated.
The capability of SAP97 to bind ADAM10, through the
SH3 domain of SAP97, and glutamate receptor subunits,
i.e., GluR1 (Leonard et al., 1998) and NR2A (Bassand et al.,
1999), via its PDZ domains, was analyzed by coimmuno-
precipitation experiments.
In Hp of AD cases compared with HC, ADAM10/SAP97
coimmunoprecipitation was reduced (33.7  4.9%, p 
Fig. 2. SAP97 capability to associate to both A disintegrin and metalloprot
hippocampus (Hp). (A) Homogenate from Hp and superior frontal gyrus
anti-ADAM10 antibody and SAP97 presence was evaluated. ADAM10/SA
differences were detectable in SFG. (B) Homogenate from Hp and SFG of H
presence was evaluated. GluR1/SAP97 association is increased in AD pat
Homogenate from Hp and SFG of HC and AD patients was immunoprecipi
association is not modified in AD patients compared with HC. No differen
percentage of HC in the same experiment.0.001; Fig. 2A). No differences were detectable between the Htwo groups in SFG (26.9  21.0, p  0.05; Fig. 2A).
Coimmunoprecipitation experiments revealed a significant
increase of GluR1/SAP97 coprecipitation in Hp homoge-
nates of AD patients, when compared with HC (90.3 
34.2%, p  0.04; Fig. 2B). In the SFG of AD cases com-
pared with HC, no alterations were observed (21.1 
18%, p  0.05; Fig. 2B).
Western blot analyses of NR2A/SAP97 immunocomplex
showed no significant differences between AD and HC
subjects in Hp (28.3  21.5%, p  0.05; Fig. 2C).
ecause NR2A expression levels were reduced in SFG (Fig.
E) coimmunoprecipitation assays were performed precip-
tating the unchanged protein, i.e., SAP97. Coimmunopre-
ipitation assays of NR2A/SAP97 complex were performed
rom SFG homogenates and no significant alterations were
ound (17.3  9.8%, p  0.05; Fig. 2C).
These data point to an alteration of SAP97 capability to
ind ADAM10 and GluR1, but not NR2A, in AD Hp.
.4. SAP97 binding capacity is modified in AD
atients’ Hp
To further confirm these results and to assess SAP97
inding capacity in an in vitro system, pull-down experi-
ents were carried out. For each binding partner, fusion
roteins between GST and the domains of ADAM10,
luR1, and NR2A responsible for the interaction with
AP97 were generated, purified, and incubated with either
0 (ADAM10) and GluR1 is changed in Alzheimer disease (AD) patients’
of healthy controls (HC) and AD patients was immunoprecipitated with
ssociation is reduced in AD patients compared with HC (p  0.001). No
D patients was immunoprecipitated with anti-GluR1 antibody and SAP97
mpared with HC (p  0.04). No differences were detectable in SFG. (C)
th anti-SAP97 antibody and NR2A presence was evaluated. SAP97/NR2A
e detectable in SFG. Quantitative analysis of immunostaining is shown aseinase 1
(SFG)
P97 a
C and A
ients co
tated wi
ces werp or SFG homogenate of AD and HC.
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422.e7E. Marcello et al. / Neurobiology of Aging 33 (2012) 422.e1–422.e10Pull-down assays were performed and Western blot anal-
ysis revealed a band corresponding to SAP97, as expected.
Quantitative analyses showed a significant increase of en-
dogenous SAP97 binding to ADAM10 cytoplasmic tail, a
significant reduction of GluR1 C-terminal tail capability to
bind SAP97, and no alterations of SAP97 precipitation with
GST-NR2A C-terminal tail (1349–1464) in Hp of AD pa-
tients when compared with HC (ADAM10, 404.9 
24.6%, p  0.009; GluR1, 24.5  9.9%, p  0.033;
NR2A, 32.5  22.5%, p  0.05 Fig. 3A–C).
Pull-down experiments carried out from SFG samples
did not reveal any significant modification of all proteins
between the two groups (ADAM10, 69.1  66.2%;
GluR1 14.4  16.5%; NR2A, 30.9  18.2%, p  0.05;
ig. 3A–C).
Pull-down assays data mirror the results obtained by
Fig. 3. SAP97 capability to pull-down A disintegrin and metalloproteinase
Alzheimer disease (AD) patients. (A) Glutathione S-transferase (GST)-ADA
homogenate from Hp and superior frontal gyrus (SFG) of AD patients and h
antibody. SAP97 amount pulled down by GST–ADAM10 C-terminal fusio
o alterations are detectable in SFG. (B) GST-GluR1 C-terminal tail fusion
FG of AD and HC. WB analysis was performed with anti-SAP97 antibo
D Hp compared with HC (p  0.033) while no alterations are detectabl
n a pull-down assay with total homogenate from Hp and SFG of AD and
etectable in both areas between AD patients and HC. (D) In Hp, the levels
f SAP97 precipitated by ADAM10 tail (correlation analysis with Pearson
n GST staining. For all experiments quantitative analysis of immunostaimmunoprecipitation analyses. In AD patients’ Hp a reduc- iion of ADAM10/SAP97 complex entails an increased
vailability of SAP97 to bind in vitro ADAM10 cytoplas-
ic tail, as demonstrated by the pull-down assay. On the
ther hand, in AD Hp, GluR1/SAP97 association is en-
anced and consequently in vitro experiments showed a
educed binding of SAP97 to GluR1 tail.
Correlation analysis of data obtained by pull-down experi-
ents with Pearsons method, revealed that SAP97 binding to
luR1 correlates with ADAM10 binding in Hp (p 0.03, Fig.
D), but not in SFG (p  0.336, Fig. 3D). These results
uggest an interdependence between the alterations of
DAM10 and GluR1 binding to SAP97 in Hp of AD patients.
. Discussion
Although the etiology of AD remains unclear, the lead-
DAM10) and GluR1, but not NR2A, is modified in hippocampus (Hp) of
-terminal tail fusion protein was incubated in a pull-down assay with total
ontrols (HC). Western blot (WB) analysis was performed with anti-SAP97
in is significantly higher in AD Hp compared with HC (p  0.009) while
was incubated, in a pull-down assay, with total homogenate from Hp and
P97 pulled down by GST–GluR1 C-terminal fusion protein is reduced in
. (C) GST-NR2A C-terminal (1349–1464) fusion protein was incubated
B analysis was performed with anti-SAP97 antibody. No differences were
7 pulled down by GluR1 C-terminal tail negatively correlate to the amount
: p  0.031). No correlation was present in SFG. All data were normalized
shown as percentage of HC in the same experiment.10 (A
M10 C
ealthy c
n prote
protein
dy. SA
e in SFG
HC. W
of SAP9
methodng hypothesis is that accumulation of A peptide is the
i
b
c
e
t
i
e
n
p
t
p
i
p
t
b
f
t
i
1
N
i
i
a
t
p
s
s
a
a
f
r
m
d
M
p
r
c
i
A
p
t
e
s
s
s
i
a
c
s
m
a
i
a
i
l
r
a
d
t
r
s
s
i
p
p
l
l
o
i
r
p
b
p
d
A
422.e8 E. Marcello et al. / Neurobiology of Aging 33 (2012) 422.e1–422.e10causative event of the pathogenesis (Hardy and Selkoe,
2002). Nevertheless, studies in patients failed to demon-
strate a clear correlation between A plaques and cognitive
mpairment. On a different ground, a higher correlation has
een shown between the loss of synapses and decreased
ognitive function (Terry et al., 1991). Lately, this led to the
merging concept that AD pathogenesis has to be considered
he result of a complex interplay of crossing pathways involv-
ng amyloid cascade and synaptic dysfunction (Bossy-Wetzel
t al., 2004). The complete comprehension of the mecha-
ism(s) through which these two main components of AD
athogenesis reciprocally interact and influence each other
urned out as more and more important to reach a complete
icture of the disease’s molecular pathogenesis.
In the last few years, several studies aimed at understand-
ng precisely how A accumulation and assembly compro-
mise synaptic structure and function of excitatory synapses,
taking advantage of synthetic or cell-derived A aggre-
gates. This has become the centerpiece of therapeutically
oriented research on the disease (Selkoe, 2008). Several
studies hypothesized a direct action of A peptides and
oligomers on the postsynaptic membrane of excitatory syn-
apse, describing in in vitro systems an interference of A on
glutamate receptor trafficking and function and on spine
formation (Lacor et al., 2007; Shankar et al., 2007, 2008;
Snyder et al., 2005). However, cellular and molecular tar-
gets of A and/or early molecular events initiating the
rocess of synaptic failure are still unknown.
In this study, we changed perspective and tried to address
he question by studying possible intraneuronal pathways
ridging synaptic function and amyloid production. We
ocused on SAP97, a cargo protein responsible not only for
he trafficking of ionotropic glutamate receptor subunits,
.e., GluR1 (Leonard et al., 1998) and NR2A (Bassand et al.,
999), but also for the synaptic localization of -secretase
ADAM10 (Marcello et al., 2007). Therefore, SAP97 is
involved in both functional organization of the glutamater-
gic synapse (Gardoni et al., 2008; Garner et al., 2000) and
modulation of -secretase activity (Marcello et al., 2007).
otably a dysfunction of SAP97 has been already reported
n AD patients brain (Wakabayashi et al., 1999), as well as
n other neurological disorders (Nash et al., 2005; Sato et
l., 2008).
The aim of our study was to investigate possible altera-
ions of SAP97 complexes with its partners in the earlier
hases of AD pathogenesis, when APP metabolism is
hifted toward amyloidogenesis but the loss of synaptic
tructure is not prominent. To this, we exploited autoptic Hp
nd SFG, respectively as an affected and a less affected
rea, obtained from late onset AD patients, fulfilling criteria
or Braak 4 stage, and age-matched control subjects.
We precisely defined our experimental design because
esults in the literature describing alterations of the gluta-
atergic synapses of AD patients at different stages of theisease are unfortunately very variable (Gylys et al., 2004; masliah et al., 2001; Mukaetova-Ladinska et al., 2000). At
resent our knowledge is a mosaic of several different
esults, not always obtained in comparable experimental
onditions.
In light of these considerations, first of all we character-
zed APP metabolism and synaptic structural composition.
s confirmed by the measurements of the amyloid cascade
roducts, at this stage of disease APP metabolism is shifted
oward amyloidogenesis only in Hp and not in SFG. In our
xperimental conditions, biochemical analyses of both pre-
ynaptic proteins and the major PSD components demon-
trated that the presynapse and the postsynaptic structure are
till not affected in both areas.
Here we showed an alteration of SAP97 capability to
nteract with its binding partners just in vulnerable brain
reas of AD patients at initial stages, thus suggesting SAP97
argo dysfunction as an early mechanism of pathogenesis.
In Hp of AD patients, levels of ADAM10 and GluR1 at
ynaptic membranes are respectively reduced and aug-
ented, while NR2A localization is not affected. These
lterations are specific because no modifications were found
n SFG.
Important insights may be gleaned from our findings,
dding new pieces to the puzzle in understanding how A
formation is upregulated in sporadic AD. Our results sug-
gest that at this stage of the disease the reduction of -secre-
tase activity could be ascribed to a defect in ADAM10
trafficking rather than to an alteration of its expression.
Indeed, it turned out that -secretase activity is reduced only
n Hp of AD patients, the brain area where ADAM10
ocalization at postsynaptic membranes is impaired.
Furthermore, membrane protein trafficking has a pivotal
ole not only in the process leading to A formation, but
lso in the mechanisms regulating synaptic function. In-
eed, molecular memory and learning-related synaptic plas-
icity take advantage of receptor trafficking, insertion and
emoval to finely modulate both long term maintenance of
ynaptic transmission and acute changes in synaptic
trength (Newpher and Ehlers, 2008). In particular, changes
n AMPA receptor levels have been implicated in the ex-
ression and maintenance of activity-dependent synaptic
lasticity phenomena, i.e., long term potentiation (LTP) and
ong term depression (LTD) (Bredt and Nicoll, 2003; Col-
ingridge et al., 2004). Therefore, the increased localization
f GluR1 at the synaptic site in AD Hp could reflect an
mpairment of dynamic regulation of the number of synaptic
eceptors, thus probably being involved in the pathogenic
rocesses responsible for synaptic dysfunction.
The altered localization of ADAM10 and GluR1 could
e ascribed to a failure of SAP97 to properly bind these
artners. Both immunoprecipitation and pull-down assays
emonstrated that SAP97 failed to correctly couple to
DAM10 and GluR1, but not to NR2A, in AD Hp.
The observations that ADAM10/SAP97 complex isarkedly reduced and that GluR1/SAP97 interaction is sig-
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422.e9E. Marcello et al. / Neurobiology of Aging 33 (2012) 422.e1–422.e10nificantly increased in Hp of AD patients indicates altera-
tions of SAP97 as a key element of molecular pathogenesis
of the disease. Indeed, SAP97 has been previously de-
scribed as a determinant for the activity of the -secretase
nzyme ADAM10. A disruption of ADAM10/SAP97 com-
lex in rodents led to a reduction of ADAM10 localization
t postsynaptic sites and to a shift of APP metabolism
oward the amyloidogenic pathway (Marcello et al., 2007).
oreover, GluR1 interactions seem to dominate the regu-
ation of exocytosis during long term potentiation (Shepherd
nd Huganir, 2007): the PDZ ligand on GluR1 appears
ritical for activity-dependent trafficking of AMPA receptor
urface, and expression (Piccini and Malinow, 2002) and
nducible exocytosis are impaired when the C-terminus is
utated (Passafaro et al., 2001).
In addition, the altered binding affinity to cytoplasmic
ails of ADAM10 and GluR1 in AD Hp is strictly interde-
endent. This negative correlation suggests that a modifi-
ation of SAP97 function in AD pathogenesis could lead to
reduced ADAM10 delivery to the postsynaptic membrane,
hus shifting APP metabolism toward amyloidogenesis, and
o an increased localization of GluR1 which impairs synap-
ic function.
In conclusion, this study sheds light on an open question
n AD research concerning the mutual interaction between
ifferent pathways of pathogenesis. In particular, we depict
new mechanism of pathogenesis which goes beyond both
myloid production/release in the extracellular fluids and
eleterious effects of A on neighboring cells, but rather
oints to a dysfunction of a key intracellular process: local
rotein trafficking and synapse assembly.
This new vision may help not only in indicating SAP97
s a point of convergence between amyloid cascade and
ynaptic function, but also in a different interpretation of
D which in this new context can be perceived as synaptic
rafficking defect pathology.
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